CDMO Avid Bioservices is being acquired by the private equity firms GHO Capital Partners and Ampersand Capital Partners. Avid specializes in manufacturing biologic products for companies at all stages of development.
Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy. Forge specializes in manufacturing AAV vectors used to deliver these therapies.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Baxter International is selling its biopharma solutions business to private equity firms. The transaction is part of a broader trend in which life science firms are spinning out or selling operations in order to hone the focus of the remaining business on certain areas.
VintaBio manufactures AAV and lentiviral vectors for entities pursuing clinical development of cell and gene therapies. The contract development manufacturing organization’s launch comes as demand for viral vectors continues to outpace the supply of these crucial components of the therapies.
Tie-ups of candy makers and nutritional product companies into a single firm called Bettera has culminated in a $1 billion acquisition by Catalent. The global contract manufacturing giant plans to leverage Bettera’s ability to produce gummies and chewables as a way to offer its customers new formulation options for nutraceutical products.
Brammer specializes in contract services for viral vector-based gene therapies. Panelists at a conference last week stressed the importance of manufacturing for gene therapy investors.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.